FDA 483 - Resilience Boston Inc. - October 10, 2008
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Genzyme Corporation in Allston, MA, revealed numerous deficiencies in drug manufacturing processes. Key issues included inadequate bioburden monitoring, poor control over batch production records, and insufficient documentation for manufacturing activities. The inspection also identified problems with aseptic processing qualification, equipment maintenance, and incomplete deviation files, indicating a broad lack of adherence to good manufacturing practices.
ID · d15a0fc2-9592-4783-a8f6-b356057855b5